T3D 959

Drug Profile

T3D 959

Alternative Names: DB-959; DB-959Na; T3D-959

Latest Information Update: 21 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer DARA BioSciences; T3D Therapeutics
  • Class Antihyperglycaemics; Insulin sensitisers; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Alzheimer's disease
  • Discontinued Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2016 Interim efficacy and adverse events data from a phase IIa trial in Alzheimer's presented at the Alzheimer's Association International Conference 2016 (AAIC-2016)
  • 28 Jul 2016 T3D Therapeutics initiates a FDA-approved extension study in Alzheimer’s disease in USA before July 2016
  • 01 Jul 2015 Phase-I/II clinical trials in Alzheimer's disease (In the elderly, In adults) in USA (PO) (NCT02560753)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top